A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk

PHASE4CompletedINTERVENTIONAL
Enrollment

245

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
DyslipidemiaHypertension
Interventions
DRUG

Amlodipine besylate

Amlodipine besylate 5 mg

DRUG

Amlodipine besylate/atorvastatin calcium single pill combination

Amlodipine/atorvastatin single pill combination 10/20 mg

DRUG

Amlodipine besylate

Amlodipine besylate 10 mg

DRUG

Amlodipine besylate/atorvastatin calcium single pill combination

Amlodipine/atorvastatin single pill combination 5/20 mg

Trial Locations (51)

11229

Pfizer Investigational Site, Brooklyn

14209

Pfizer Investigational Site, Buffalo

19020

Pfizer Investigational Site, Bensalem

19146

Pfizer Investigational Site, Philadelphia

19446

Pfizer Investigational Site, Lansdale

23320

Pfizer Investigational Site, Chesapeake

29445

Pfizer Investigational Site, Goose Creek

29464

Pfizer Investigational Site, Mt. Pleasant

30084

Pfizer Investigational Site, Tucker

30904

Pfizer Investigational Site, Augusta

32605

Pfizer Investigational Site, Gainesville

32935

Pfizer Investigational Site, Melbourne

33176

Pfizer Investigational Site, Miami

33701

Pfizer Investigational Site, St. Petersburg

34695

Pfizer Investigational Site, Safety Harbor

34741

Pfizer Investigational Site, Kissimmee

35209

Pfizer Investigational Site, Birmingham

35216

Pfizer Investigational Site, Birmingham

35234

Pfizer Investigational Site, Birmingham

37620

Pfizer Investigational Site, Bristol

37660

Pfizer Investigational Site, Kingsport

41018

Pfizer Investigational Site, Erlanger

45219

Pfizer Investigational Site, Cincinnati

45242

Pfizer Investigational Site, Cincinnati

46601

Pfizer Investigational Site, South Bend

48091

Pfizer Investigational Site, Warren

55404

Pfizer Investigational Site, Minneapolis

63017

Pfizer Investigational Site, Chesterfield

63031

Pfizer Investigational Site, Florissant

73103

Pfizer Investigational Site, Oklahoma City

74136

Pfizer Investigational Site, Tulsa

75093

Pfizer Investigational Site, Plano

75235

Pfizer Investigational Site, Dallas

78238

Pfizer Investigational Site, San Antonio

85206

Pfizer Investigational Site, Mesa

89014

Pfizer Investigational Site, Henderson

89015

Pfizer Investigational Site, Henderson

90502

Pfizer Investigational Site, Torrance

92688

Pfizer Investigational Site, Rancho Santa Margarita

92692

Pfizer Investigational Site, Mission Viejo

92843

Pfizer Investigational Site, Garden Grove

04210

Pfizer Investigational Site, Auburn

68116-2004

Pfizer Investigational Site, Omaha

07823

Pfizer Investigational Site, Belvidere

08807

Pfizer Investigational Site, Bridgewater

07013

Pfizer Investigational Site, Clifton

07202

Pfizer Investigational Site, Elizabeth

08844

Pfizer Investigational Site, Hillsborough

08618

Pfizer Investigational Site, Trenton

02904

Pfizer Investigational Site, Providence

77030-2324

Pfizer Investigational Site, Houston

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00412113 - A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk | Biotech Hunter | Biotech Hunter